The mechanism of action of glatiramer acetate treatment in multiple sclerosis

Michael K. Racke, Amy E. Lovett-Racke, Nitin J. Karandikar

Research output: Contribution to journalArticle

85 Scopus citations

Abstract

Objective: Glatiramer acetate (formerly known as copolymer 1) is the major noninterferon immunomodulatory agent used in the treatment of relapsing-remitting multiple sclerosis. Its mechanism of action over the past 40 years has evolved with our understanding of the immune response. Methods: We review the various mechanisms that have been proposed for this random polymer over the years, with emphasis on recent methods that utilize modern immunologic techniques. Results: Studies describing processes such as immune deviation and effects on regulatory T cells and antigen-presenting cells are presented. Conclusions: Effects of glatiramer acetate on the immune response have evolved as our technical abilities and knowledge of the immune response itself have developed.

Original languageEnglish (US)
Pages (from-to)S25-S30
JournalNeurology
Volume74
Issue number1 SUPPL.
DOIs
StatePublished - Jan 2010

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'The mechanism of action of glatiramer acetate treatment in multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Racke, M. K., Lovett-Racke, A. E., & Karandikar, N. J. (2010). The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology, 74(1 SUPPL.), S25-S30. https://doi.org/10.1212/WNL.0b013e3181c97e39